Domestic drug makers rush to develop amlodipine preparations
Korea's pharmaceutical firms are scrambling to develop the first-generic versions of Pfizer Korea's Norvasc valued at 150 billion won last year and the foreign-invested pharmaceutical firm is expected to face an uphill battle in Korea from next year due to expected fierce competition from...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
